BRPI0914004A2 - agentes de aglutinação de receptor notch1 e métodos de uso mesmo - Google Patents
agentes de aglutinação de receptor notch1 e métodos de uso mesmoInfo
- Publication number
- BRPI0914004A2 BRPI0914004A2 BRPI0914004A BRPI0914004A BRPI0914004A2 BR PI0914004 A2 BRPI0914004 A2 BR PI0914004A2 BR PI0914004 A BRPI0914004 A BR PI0914004A BR PI0914004 A BRPI0914004 A BR PI0914004A BR PI0914004 A2 BRPI0914004 A2 BR PI0914004A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor binding
- binding agents
- use methods
- same use
- notch1 receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7909508P | 2008-07-08 | 2008-07-08 | |
US11269908P | 2008-11-07 | 2008-11-07 | |
US11270108P | 2008-11-07 | 2008-11-07 | |
PCT/US2009/003995 WO2010005567A2 (en) | 2008-07-08 | 2009-07-08 | Notch1 receptor binding agents and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0914004A2 true BRPI0914004A2 (pt) | 2015-11-17 |
Family
ID=41507637
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0914004A BRPI0914004A2 (pt) | 2008-07-08 | 2009-07-08 | agentes de aglutinação de receptor notch1 e métodos de uso mesmo |
BRPI0914007A BRPI0914007A2 (pt) | 2008-07-08 | 2009-07-08 | anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0914007A BRPI0914007A2 (pt) | 2008-07-08 | 2009-07-08 | anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos |
Country Status (32)
Country | Link |
---|---|
US (11) | US8435513B2 (pt) |
EP (4) | EP2307459B1 (pt) |
JP (2) | JP5560271B2 (pt) |
KR (2) | KR101682490B1 (pt) |
CN (3) | CN102316897B (pt) |
AU (2) | AU2009269095B2 (pt) |
BR (2) | BRPI0914004A2 (pt) |
CA (2) | CA2729602A1 (pt) |
CO (2) | CO6390041A2 (pt) |
CR (1) | CR20110069A (pt) |
CY (2) | CY1116195T1 (pt) |
DK (2) | DK2307051T3 (pt) |
DO (2) | DOP2011000002A (pt) |
EA (2) | EA201170157A1 (pt) |
ES (2) | ES2531541T3 (pt) |
HK (2) | HK1151296A1 (pt) |
HR (2) | HRP20150256T1 (pt) |
IL (2) | IL210221A (pt) |
MA (2) | MA32448B1 (pt) |
ME (2) | ME02069B (pt) |
MX (2) | MX2011000236A (pt) |
MY (2) | MY159815A (pt) |
NZ (2) | NZ590131A (pt) |
PL (2) | PL2307459T3 (pt) |
PT (2) | PT2307051E (pt) |
RS (2) | RS53750B1 (pt) |
SG (2) | SG192468A1 (pt) |
SI (2) | SI2307459T1 (pt) |
SM (2) | SMT201500047B (pt) |
UA (1) | UA101672C2 (pt) |
WO (2) | WO2010005566A2 (pt) |
ZA (2) | ZA201009280B (pt) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US9540694B2 (en) * | 2006-05-19 | 2017-01-10 | The Johns Hopkins University | HEYL as a therapeutic target and a diagnostic marker for neoplasia and uses therefor |
CA2655362A1 (en) | 2006-06-13 | 2007-12-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
NZ577274A (en) | 2006-12-18 | 2012-10-26 | Genentech Inc | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
NZ590131A (en) | 2008-07-08 | 2012-10-26 | Oncomed Pharm Inc | Notch-binding agents and antagonists and methods of use thereof |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
US8404239B2 (en) * | 2008-10-01 | 2013-03-26 | Genentech, Inc. | Anti-Notch2 NRR antibodies |
MX337468B (es) | 2009-06-18 | 2016-03-02 | Pfizer | Anticuerpos anti notch-1. |
AU2010300747A1 (en) * | 2009-09-30 | 2012-04-26 | Genentech, Inc. | Treating Notch1-antagonist-resistant cancer (s) using Notch3 antagonists |
ES2575152T3 (es) | 2009-10-16 | 2016-06-24 | Oncomed Pharmaceuticals, Inc. | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores |
MX2012008085A (es) | 2010-01-13 | 2012-09-12 | Oncomed Pharm Inc | Agentes de union notch1 y metodos de uso de los mismos. |
US9427429B2 (en) | 2010-03-01 | 2016-08-30 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
KR20130079384A (ko) * | 2010-05-03 | 2013-07-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
RU2622083C2 (ru) | 2010-12-15 | 2017-06-09 | ВАЙЕТ ЭлЭлСи | Антитела против notch1 |
US20130058947A1 (en) * | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
SG11201400526TA (en) * | 2011-09-12 | 2014-04-28 | Tau Therapeutics Llc | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
HUE042192T2 (hu) | 2011-09-23 | 2019-06-28 | Oncomed Pharm Inc | VEGF/DLL4-kötõ ágensek és alkalmazásaik |
TW201329105A (zh) * | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類notch1引誘物 |
US20130089562A1 (en) | 2011-10-05 | 2013-04-11 | Genenthech, Inc. | Methods of treating liver conditions using notch2 antagonists |
EP2780354A4 (en) * | 2011-11-16 | 2015-06-24 | Oncomed Pharm Inc | HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE |
KR101535219B1 (ko) * | 2011-11-18 | 2015-07-09 | 한국생명공학연구원 | Notch3에 대한 인간 단일클론항체 |
US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
WO2013173542A1 (en) * | 2012-05-16 | 2013-11-21 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch2/3 antibodies |
JP6352264B2 (ja) | 2012-08-13 | 2018-07-04 | ジェネンテック, インコーポレイテッド | 抗jagged抗体および使用方法 |
EP2897643A4 (en) * | 2012-09-21 | 2016-04-20 | Oncomed Pharm Inc | METHOD FOR THE TREATMENT OF MOLECULAR BLOOD DISEASES WITH NOTCH1 ANTIBODIES |
AU2013330433B2 (en) * | 2012-10-09 | 2016-06-16 | Sanbio, Inc. | Methods and compositions for treatment of retinal degeneration |
WO2014071018A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
TW201431880A (zh) | 2012-11-07 | 2014-08-16 | Pfizer | 抗切口3(anti-notch3)抗體及抗體-藥物共軛體 |
WO2014100435A1 (en) * | 2012-12-19 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-notch3 antibodies |
GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
SG10201803131TA (en) * | 2013-02-18 | 2018-06-28 | Univ Health Network | Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells |
US9944700B2 (en) | 2013-03-13 | 2018-04-17 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
EP2970479B1 (en) * | 2013-03-14 | 2019-04-24 | Novartis AG | Antibodies against notch 3 |
MA38495A1 (fr) | 2013-03-15 | 2017-08-31 | Genentech Inc | Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques |
MX2015011386A (es) * | 2013-03-15 | 2016-02-03 | Oncomed Pharm Inc | Metodo para tratar cancer pancreatico. |
TW201902515A (zh) | 2014-02-12 | 2019-01-16 | 美商建南德克公司 | 抗jagged1抗體及使用方法 |
WO2015153997A2 (en) * | 2014-04-04 | 2015-10-08 | Oncomed Pharmaceuticals, Inc. | Notch3 antibodies and uses thereof |
BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
GB201416832D0 (en) * | 2014-09-24 | 2014-11-05 | Glaxosmithkline Plc | Methods of treatment |
US11370823B2 (en) | 2014-10-29 | 2022-06-28 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
AU2015338974B2 (en) * | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
CN105986001B (zh) * | 2015-02-12 | 2019-12-03 | 上海交通大学 | 一种基于膜结合蛋白和荧光互补的高通量猎物拮抗剂筛选方法 |
CN108064283B (zh) * | 2015-02-24 | 2024-01-09 | 加利福尼亚大学董事会 | 结合触发的转录开关及其使用方法 |
TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
ES2818184T3 (es) * | 2015-04-16 | 2021-04-09 | Eisai R&D Man Co Ltd | Anticuerpo anti-Notch 4 humano |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
CN105585636B (zh) * | 2015-11-24 | 2020-03-03 | 南方医科大学 | 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用 |
EA201892096A1 (ru) * | 2016-03-16 | 2019-08-30 | Эйбоум Корпорейшн | Нейтрализующие моноклональные антитела к il-25 и их применение |
ES2931955T3 (es) | 2016-04-29 | 2023-01-05 | Aveo Pharmaceuticals Inc | Anticuerpo anti-Notch3 |
US11400116B2 (en) | 2016-05-06 | 2022-08-02 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
US11026996B2 (en) * | 2016-05-25 | 2021-06-08 | The Trustees Of Columbia University In The City Of New York | Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling |
SG10201913583QA (en) | 2016-08-23 | 2020-02-27 | Univ California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
JP2020500033A (ja) * | 2016-11-07 | 2020-01-09 | ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー | ライム病に対する使用のためのdna抗体構築物 |
WO2018183216A1 (en) | 2017-03-27 | 2018-10-04 | The Schepens Eye Research Institute, Inc. | Notch3 agonist compositions and methods for treating small vessel diseases |
CN107557343B (zh) * | 2017-08-09 | 2020-09-25 | 苏州大学附属儿童医院 | 抗人dll4单克隆抗体3f9 |
US11590152B2 (en) | 2018-01-26 | 2023-02-28 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss |
CA3096812A1 (en) * | 2018-04-10 | 2019-10-17 | Stichting Sanquin Bloedvoorziening | Chimeric notch receptors |
CN113227128A (zh) * | 2018-07-20 | 2021-08-06 | 香港理工大学 | 针对抑制jag1-notch1信号通路的肽 |
WO2020097155A1 (en) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
CN111334575A (zh) * | 2020-02-18 | 2020-06-26 | 至本医疗科技(上海)有限公司 | Notch家族基因变异在预测实体瘤患者对免疫检查点抑制剂疗法敏感性中的应用 |
TW202216780A (zh) | 2020-07-17 | 2022-05-01 | 美商建南德克公司 | 抗notch2抗體及其使用方法 |
CN112625125B (zh) * | 2021-01-18 | 2021-12-14 | 中国人民解放军军事科学院军事医学研究院 | 一株中和新型冠状病毒感染的单抗 |
WO2022272283A1 (en) * | 2021-06-24 | 2022-12-29 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Dual egfr-muc1 chimeric antigen receptor t cells |
US20230322958A1 (en) * | 2022-01-19 | 2023-10-12 | Genentech, Inc. | Anti-Notch2 Antibodies and Conjugates and Methods of Use |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US6344321B1 (en) | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
DE69229482T2 (de) * | 1991-04-25 | 1999-11-18 | Chugai Pharmaceutical Co Ltd | Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor |
IE20030749A1 (en) | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them |
US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US20050112121A1 (en) * | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5756291A (en) | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
DE4425115A1 (de) | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
WO1996036361A1 (en) * | 1995-05-18 | 1996-11-21 | The Regents Of The University Of Michigan | Dna binding antibodies |
PT859841E (pt) | 1995-08-18 | 2002-11-29 | Morphosys Ag | Bibliotecas de proteinas/ (poli) peptidos |
US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
AU2160297A (en) | 1996-03-30 | 1997-10-22 | Boehringer Mannheim Gmbh | Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors |
EP0921818A4 (en) * | 1996-05-31 | 2002-09-25 | Nat American Red Cross | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON JAGGED / NOTCH PROTEINS AND AMINO ACIDS |
FR2751986B1 (fr) * | 1996-08-01 | 1998-12-31 | Inst Nat Sante Rech Med | Gene implique dans le cadasil, methode de diagnostic et application therapeutique |
IL129531A0 (en) | 1996-11-07 | 2000-02-29 | Lorantis Ltd | Ligands to notch proteins |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US6379925B1 (en) * | 1997-06-18 | 2002-04-30 | The Trustees Of Columbia University In The City Of New York | Angiogenic modulation by notch signal transduction |
WO1998057621A1 (en) | 1997-06-18 | 1998-12-23 | The Trustees Of Columbia University In The City Ofnew York | Angiogenic modulation by notch signal transduction |
US6692919B1 (en) | 1997-07-23 | 2004-02-17 | Yale University | Activated forms of notch and methods based thereon |
US6004528A (en) * | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
AU768269B2 (en) * | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
US20030054360A1 (en) | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
US20030003572A1 (en) | 1999-03-05 | 2003-01-02 | David J. Anderson | Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression |
US20020010320A1 (en) | 1999-04-05 | 2002-01-24 | James W. Fett | Chemeric and humanized antibodies to angiogenin |
CA2339889C (en) | 1999-07-02 | 2012-01-31 | Morphosys Ag | Identification of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US20030031670A1 (en) * | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
DE10031380A1 (de) | 2000-06-28 | 2002-01-10 | Merck Patent Gmbh | Verfahren zur Übertragung von Alkyliden-Gruppen auf organischen Verbindungen |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US20020151487A1 (en) | 2000-08-31 | 2002-10-17 | Loyola University Chicago | Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway |
US6689744B2 (en) * | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
US7312325B2 (en) | 2000-09-26 | 2007-12-25 | Duke University | RNA aptamers and methods for identifying the same |
CN1395617A (zh) | 2000-10-02 | 2003-02-05 | 韩国生命工学研究院 | 抗乙肝病毒表面抗原s的人源化抗体及其制备方法 |
CA2445168A1 (en) * | 2001-04-24 | 2002-10-31 | Bayer Corporation | Human timp-1 antibodies |
US7356224B2 (en) * | 2001-07-03 | 2008-04-08 | Brown University Research Foundation | Method and apparatus for detecting multiple optical wave lengths |
WO2003042246A2 (en) | 2001-11-14 | 2003-05-22 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
AU2002364537A1 (en) | 2001-12-07 | 2003-06-23 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
GB0201674D0 (en) | 2002-01-25 | 2002-03-13 | Lorantis Ltd | Medical treatment |
EP1481090A4 (en) | 2002-02-15 | 2006-08-09 | Somalogic Inc | METHOD AND REAGENTS FOR DETECTING BINDING OF TARGET MOLECULES BY NUCLEIC ACID ELECTRODES |
JP2005530856A (ja) | 2002-06-21 | 2005-10-13 | ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | 膜関連腫瘍内皮マーカー |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
JP2006515747A (ja) * | 2002-11-01 | 2006-06-08 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
US20050124565A1 (en) | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
CA2508715A1 (en) | 2002-12-06 | 2004-06-24 | Singapore General Hospital Pte Ltd. | Materials and methods relating to treatment of injury and disease to the central nervous system |
US20070178090A1 (en) | 2003-04-01 | 2007-08-02 | Genzyme Corporation | Breast endothelial cell expression patterns |
US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
US7329742B2 (en) | 2003-09-04 | 2008-02-12 | The Regents Of The University Of California | Aptamers and methods for their in vitro selection and uses thereof |
GB0321805D0 (en) | 2003-09-18 | 2003-10-15 | Univ Wales Medicine | Human tumour growth patterns |
US7282203B2 (en) | 2003-11-26 | 2007-10-16 | Health Research, Inc. | Use of NOTCH pathway interfering agents for treatment of plasma cell disorders |
EP1718767B1 (en) | 2004-02-03 | 2012-04-11 | The Regents Of The University Of Michigan | Compositions for treating breast and pancreatic cancer |
FR2867784B1 (fr) | 2004-03-17 | 2006-06-09 | Commissariat Energie Atomique | Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications |
CA2560760A1 (en) * | 2004-03-24 | 2005-09-29 | Technion Research And Development Foundation Ltd. | Electrode |
US20050239134A1 (en) | 2004-04-21 | 2005-10-27 | Board Of Regents, The University Of Texas System | Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein |
WO2005111072A2 (en) | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
US20070077245A1 (en) | 2004-08-04 | 2007-04-05 | The Brigham And Women's Hospital, Inc. | NOTCH mutations leading to increased receptor signaling |
GB0421838D0 (en) | 2004-09-30 | 2004-11-03 | Congenia S R L | Cancer markers |
WO2006053063A2 (en) | 2004-11-05 | 2006-05-18 | The Regents Of The University Of California | Notch-1 assay to detect neurodegenerative diseases |
JP2008519829A (ja) * | 2004-11-10 | 2008-06-12 | ヒュブレヒト ラボラトリウム | Notch経路活性化の阻害による腸腺腫および/または腺癌の処置 |
CA3218940A1 (en) * | 2004-11-12 | 2006-05-18 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
EP1910557A2 (en) | 2005-04-07 | 2008-04-16 | Chiron Corporation | Cancer-related genes |
ATE498358T1 (de) | 2005-06-29 | 2011-03-15 | Compumedics Ltd | Sensoranordnung mit leitfähiger brücke |
EP1945754B1 (en) | 2005-10-31 | 2014-07-23 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2007061988A2 (en) | 2005-11-22 | 2007-05-31 | University Of Vermont And State Agricultural College | Methods for determining notch signaling and uses thereof |
EP1962895B2 (en) | 2005-12-16 | 2016-01-20 | Regeneron Pharmaceuticals, Inc. | THERAPEUTIC USE OF A Dll4 ANTAGONIST AND A VEGF INHIBITOR FOR INHIBITING TUMOR GROWTH |
WO2007075914A2 (en) | 2005-12-22 | 2007-07-05 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies against orthopoxviruses |
AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
US20080241150A1 (en) | 2006-05-15 | 2008-10-02 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 |
AR061245A1 (es) | 2006-06-06 | 2008-08-13 | Genentech Inc | Composiciones y metodos para la modulacion del desarrollo vascular |
JP2009539384A (ja) | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 抗dll4抗体および抗dll4抗体使用の方法 |
CA2655362A1 (en) | 2006-06-13 | 2007-12-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
WO2008050525A1 (fr) | 2006-09-29 | 2008-05-02 | Konica Minolta Opto, Inc. | Film retardateur |
EP2562188A3 (en) | 2006-09-29 | 2013-03-06 | OncoMed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US7700113B2 (en) * | 2006-10-19 | 2010-04-20 | Maine Medical Research Institute, A Division Of Maine Medical Center | Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2 |
BRPI0715989A8 (pt) | 2006-10-19 | 2018-03-13 | Genentech Inc | "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" |
TW200823293A (en) | 2006-10-19 | 2008-06-01 | Genentech Inc | Novel anti-Notch3 antibodies and their use in the detection and diagnosis of disease |
US20100068688A1 (en) | 2006-11-06 | 2010-03-18 | Howard Shapiro | Management of teaching processes for individualized instruction in a multistudent environment |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
NZ577274A (en) * | 2006-12-18 | 2012-10-26 | Genentech Inc | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
EP2120996A2 (en) | 2006-12-20 | 2009-11-25 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
US20100119526A1 (en) | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
WO2008100563A2 (en) * | 2007-02-14 | 2008-08-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
JP2010520280A (ja) | 2007-03-05 | 2010-06-10 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | NotchまたはNumb特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御 |
US20100099090A1 (en) * | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
MY150531A (en) * | 2007-07-16 | 2014-01-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
CN101883786A (zh) | 2007-08-23 | 2010-11-10 | 纽约哥伦比亚大学理事会 | 人源化的notch融合蛋白组合物及治疗方法 |
EP2195451A4 (en) | 2007-08-28 | 2011-01-19 | Merck Sharp & Dohme | EXPRESSION PROFILES OF BIOMARKERGENIC IN NOTCH-MEDIATED CANCER DISEASES |
US7807630B2 (en) | 2007-09-14 | 2010-10-05 | Vanderbilt University | Targeting of Notch3 receptor function for cancer therapy |
US8377886B2 (en) | 2007-09-14 | 2013-02-19 | Albert Einstein College Of Medicine Of Yeshiva University | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease |
US20120082659A1 (en) | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
US8119366B2 (en) | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
CN102056945A (zh) | 2008-04-07 | 2011-05-11 | 埃博灵克斯股份有限公司 | 针对Notch途径的单可变结构域 |
WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
NZ590131A (en) | 2008-07-08 | 2012-10-26 | Oncomed Pharm Inc | Notch-binding agents and antagonists and methods of use thereof |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
US8404239B2 (en) | 2008-10-01 | 2013-03-26 | Genentech, Inc. | Anti-Notch2 NRR antibodies |
CA2760999A1 (en) | 2009-03-13 | 2010-09-16 | Mariana Barboza | Prebiotic oligosaccharides |
AU2010300747A1 (en) | 2009-09-30 | 2012-04-26 | Genentech, Inc. | Treating Notch1-antagonist-resistant cancer (s) using Notch3 antagonists |
DE102009047243A1 (de) | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
MX2012008085A (es) | 2010-01-13 | 2012-09-12 | Oncomed Pharm Inc | Agentes de union notch1 y metodos de uso de los mismos. |
KR20120117931A (ko) | 2010-02-12 | 2012-10-24 | 온코메드 파마슈티칼스, 인크. | 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법 |
JP5450221B2 (ja) | 2010-04-14 | 2014-03-26 | 株式会社神戸製鋼所 | 高電流密度ガスシールドアーク溶接方法 |
NZ626610A (en) | 2010-05-04 | 2015-11-27 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
WO2012003472A1 (en) | 2010-07-02 | 2012-01-05 | Aveo Pharmaceuticals, Inc. | Anti-notch1 antibodies |
PT3556774T (pt) | 2011-03-11 | 2024-02-29 | Beth Israel Deaconess Medical Ct Inc | Anticorpos anti-cd40 e suas utilizações |
EP2780354A4 (en) | 2011-11-16 | 2015-06-24 | Oncomed Pharm Inc | HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE |
WO2013173542A1 (en) | 2012-05-16 | 2013-11-21 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch2/3 antibodies |
ES2848025T3 (es) | 2012-09-04 | 2021-08-05 | Eleison Pharmaceuticals LLC | Prevención de la recidiva pulmonar del cáncer con cisplatino complejado con lípidos |
EP2897643A4 (en) | 2012-09-21 | 2016-04-20 | Oncomed Pharm Inc | METHOD FOR THE TREATMENT OF MOLECULAR BLOOD DISEASES WITH NOTCH1 ANTIBODIES |
TW201431880A (zh) | 2012-11-07 | 2014-08-16 | Pfizer | 抗切口3(anti-notch3)抗體及抗體-藥物共軛體 |
MX2015011386A (es) | 2013-03-15 | 2016-02-03 | Oncomed Pharm Inc | Metodo para tratar cancer pancreatico. |
JP2017510626A (ja) | 2014-03-07 | 2017-04-13 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Notch1抗体によって癌を治療するための方法 |
WO2015153997A2 (en) | 2014-04-04 | 2015-10-08 | Oncomed Pharmaceuticals, Inc. | Notch3 antibodies and uses thereof |
-
2009
- 2009-07-08 NZ NZ590131A patent/NZ590131A/xx not_active IP Right Cessation
- 2009-07-08 PT PT97948210T patent/PT2307051E/pt unknown
- 2009-07-08 ES ES09794822.8T patent/ES2531541T3/es active Active
- 2009-07-08 WO PCT/US2009/003994 patent/WO2010005566A2/en active Application Filing
- 2009-07-08 RS RS20150120A patent/RS53750B1/en unknown
- 2009-07-08 EP EP09794822.8A patent/EP2307459B1/en active Active
- 2009-07-08 BR BRPI0914004A patent/BRPI0914004A2/pt not_active IP Right Cessation
- 2009-07-08 JP JP2011517417A patent/JP5560271B2/ja not_active Expired - Fee Related
- 2009-07-08 SG SG2013051586A patent/SG192468A1/en unknown
- 2009-07-08 ME MEP-2015-20A patent/ME02069B/me unknown
- 2009-07-08 CN CN200980126470.XA patent/CN102316897B/zh not_active Expired - Fee Related
- 2009-07-08 AU AU2009269095A patent/AU2009269095B2/en not_active Ceased
- 2009-07-08 CA CA2729602A patent/CA2729602A1/en not_active Abandoned
- 2009-07-08 MY MYPI2011000057A patent/MY159815A/en unknown
- 2009-07-08 ME MEP-2015-63A patent/ME02148B/me unknown
- 2009-07-08 NZ NZ590127A patent/NZ590127A/xx not_active IP Right Cessation
- 2009-07-08 SI SI200931146T patent/SI2307459T1/sl unknown
- 2009-07-08 US US13/003,013 patent/US8435513B2/en not_active Expired - Fee Related
- 2009-07-08 EA EA201170157A patent/EA201170157A1/ru unknown
- 2009-07-08 CA CA2729306A patent/CA2729306C/en not_active Expired - Fee Related
- 2009-07-08 JP JP2011517416A patent/JP5560270B2/ja not_active Expired - Fee Related
- 2009-07-08 CN CN201410524761.7A patent/CN104402998A/zh active Pending
- 2009-07-08 EA EA201170158A patent/EA026109B1/ru not_active IP Right Cessation
- 2009-07-08 KR KR1020117000743A patent/KR101682490B1/ko active IP Right Grant
- 2009-07-08 MY MYPI2011000058A patent/MY155603A/en unknown
- 2009-07-08 EP EP14195878.5A patent/EP2899211A1/en not_active Withdrawn
- 2009-07-08 PL PL09794822T patent/PL2307459T3/pl unknown
- 2009-07-08 DK DK09794821.0T patent/DK2307051T3/en active
- 2009-07-08 BR BRPI0914007A patent/BRPI0914007A2/pt not_active IP Right Cessation
- 2009-07-08 PT PT09794822T patent/PT2307459E/pt unknown
- 2009-07-08 RS RS20150288A patent/RS53924B1/en unknown
- 2009-07-08 PL PL09794821T patent/PL2307051T3/pl unknown
- 2009-07-08 KR KR1020117000736A patent/KR101640099B1/ko active IP Right Grant
- 2009-07-08 ES ES09794821.0T patent/ES2535614T3/es active Active
- 2009-07-08 MX MX2011000236A patent/MX2011000236A/es active IP Right Grant
- 2009-07-08 CN CN200980126471.4A patent/CN102112490B/zh not_active Expired - Fee Related
- 2009-07-08 MX MX2011000233A patent/MX2011000233A/es active IP Right Grant
- 2009-07-08 SI SI200931156T patent/SI2307051T1/sl unknown
- 2009-07-08 DK DK09794822.8T patent/DK2307459T3/da active
- 2009-07-08 EP EP09794821.0A patent/EP2307051B1/en active Active
- 2009-07-08 SG SG2013051578A patent/SG192467A1/en unknown
- 2009-07-08 EP EP14199035.8A patent/EP2924051A1/en not_active Withdrawn
- 2009-07-08 WO PCT/US2009/003995 patent/WO2010005567A2/en active Application Filing
- 2009-07-08 US US12/499,627 patent/US8226943B2/en not_active Expired - Fee Related
- 2009-08-07 UA UAA201101442A patent/UA101672C2/uk unknown
-
2010
- 2010-12-23 IL IL210221A patent/IL210221A/en not_active IP Right Cessation
- 2010-12-23 ZA ZA2010/09280A patent/ZA201009280B/en unknown
- 2010-12-23 IL IL210222A patent/IL210222A/en not_active IP Right Cessation
-
2011
- 2011-01-03 ZA ZA2011/00029A patent/ZA201100029B/en unknown
- 2011-01-03 MA MA33483A patent/MA32448B1/fr unknown
- 2011-01-03 MA MA33484A patent/MA32449B1/fr unknown
- 2011-01-05 DO DO2011000002A patent/DOP2011000002A/es unknown
- 2011-01-05 DO DO2011000004A patent/DOP2011000004A/es unknown
- 2011-02-07 CR CR20110069A patent/CR20110069A/es unknown
- 2011-02-08 CO CO11014588A patent/CO6390041A2/es active IP Right Grant
- 2011-02-08 CO CO11014579A patent/CO6612253A2/es active IP Right Grant
- 2011-05-26 HK HK11105234.2A patent/HK1151296A1/xx not_active IP Right Cessation
- 2011-05-26 HK HK11105233.3A patent/HK1151218A1/xx not_active IP Right Cessation
-
2012
- 2012-05-15 US US13/472,305 patent/US8425903B2/en not_active Expired - Fee Related
-
2013
- 2013-03-01 US US13/782,671 patent/US8945873B2/en not_active Expired - Fee Related
- 2013-03-13 US US13/801,613 patent/US8945874B2/en not_active Expired - Fee Related
- 2013-03-14 US US13/826,284 patent/US8945547B2/en active Active
- 2013-03-14 US US13/826,432 patent/US8980260B2/en active Active
-
2014
- 2014-12-19 US US14/577,484 patent/US9499613B2/en not_active Expired - Fee Related
-
2015
- 2015-01-20 US US14/600,641 patent/US9505832B2/en active Active
- 2015-03-02 SM SM201500047T patent/SMT201500047B/xx unknown
- 2015-03-03 CY CY20151100227T patent/CY1116195T1/el unknown
- 2015-03-06 HR HRP20150256AT patent/HRP20150256T1/hr unknown
- 2015-04-24 CY CY20151100376T patent/CY1116230T1/el unknown
- 2015-04-24 HR HRP20150443TT patent/HRP20150443T1/hr unknown
- 2015-05-20 SM SM201500120T patent/SMT201500120B/xx unknown
-
2016
- 2016-08-16 AU AU2016216568A patent/AU2016216568A1/en not_active Abandoned
- 2016-10-12 US US15/291,334 patent/US20170183405A1/en not_active Abandoned
- 2016-10-20 US US15/298,527 patent/US20170198031A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0914004A2 (pt) | agentes de aglutinação de receptor notch1 e métodos de uso mesmo | |
BRPI0820387A2 (pt) | Agentes de ligação de wise e epítopos | |
BRPI0911563A2 (pt) | uso de antagonista da progesterona | |
BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
BRPI0915717A2 (pt) | ferramenta de avaliação de cascalho e métodos de uso | |
BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
DK2349430T3 (da) | KATETERISERINGANORDNING og -kit | |
BRPI0906435A2 (pt) | anticorpos anti-cd79b e imunoconjugados e métodos de uso | |
BRPI0821090A2 (pt) | Moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo | |
BRPI0912703A2 (pt) | composições imuno-moduladoras e métodos para uso dessas | |
BRPI0808684A2 (pt) | moduladores de tgr5 e métodos de uso destes | |
DOP2010000260A (es) | Derivado heterociclico fusionado y su uso | |
BRPI0913188A2 (pt) | moduladores de receptores 5-ht3, métodos de fabricação, e uso dos mesmos | |
BRPI0909954A2 (pt) | "diazacarbazóis e métodos de uso" | |
BRPI0816835A2 (pt) | dispositivo de pulverização e método de uso do mesmo | |
BRPI0806964A2 (pt) | Combinações de agonístico beta-2-adrenoceptor e benzotiazolona | |
BRPI0919794A2 (pt) | dispositivo para uso intracorpóreo, e, composto | |
BRPI0813457A2 (pt) | Composto de organoenxofre contendo halogênio e uso do mesmo | |
BRPI0913325A2 (pt) | interface de usuário para dispositivo de teste | |
BRPI0909840A2 (pt) | Uso de 4-tio-2-deoxinucleosídios | |
BRPI1009257A2 (pt) | antagonista receptor de mineralocorticoide e métodos de uso. | |
BRPI0917019A2 (pt) | dispositivo de cimentação e método | |
EP2273266A4 (en) | PARASPORIN-1 RECEPTOR AND USE THEREOF | |
ES1070297Y (es) | Dispositivo para limpieza y automasaje de la espalda | |
BRPI0922008A2 (pt) | compostos e respectivos metodos de preparação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |